Anti-PD1/PD-L1 directed immune-checkpoint-inhibitors (ICI) are widely used to treat patients with advanced non-small cell lung cancer (NSCLC). The activity of ICI across NSCLC harboring oncogenic alterations is poorly characterized. The aim of our study was to address the efficacy of ICI in the context of oncogenic addiction.
Titolo: | Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry |
Autori Riconosciuti: | |
Autori: | Mazières, J; Drilon, A; Lusque, A; Mhanna, L; Cortot, A B; Mezquita, L; Thai, A A; Mascaux, C; Couraud, S; Veillon, R; Van Den Heuvel, M; Neal, J; Peled, N; Früh, M; Ng, T L; Gounant, V; Popat, S; Diebold, J; Sabari, J; Zhu, V W; Rothschild, S I; Bironzo, P; Martinez, A; Curioni-Fontecedro, A; Rosell, R; Lattuca-Truc, M; Wiesweg, M; Besse, B; Solomon, B; Barlesi, F; Schouten, R D; Wakelee, H; Camidge, D R; Zalcman, G; Novello, S; Ou, S I; Milia, J; Gautschi, O |
Data di pubblicazione: | 2019 |
Abstract: | Anti-PD1/PD-L1 directed immune-checkpoint-inhibitors (ICI) are widely used to treat patients with advanced non-small cell lung cancer (NSCLC). The activity of ICI across NSCLC harboring oncogenic alterations is poorly characterized. The aim of our study was to address the efficacy of ICI in the context of oncogenic addiction. |
Pagina iniziale: | /// |
Pagina finale: | /// |
Digital Object Identifier (DOI): | 10.1093/annonc/mdz167 |
Parole Chiave: | Immunotherapy-lung cancer-oncogenic addiction |
Rivista: | ANNALS OF ONCOLOGY |
Appare nelle tipologie: | 03A-Articolo su Rivista |
File in questo prodotto:
File | Descrizione | Tipologia | Licenza | |
---|---|---|---|---|
mdz167.pdf | 1 Ver. finale autore | Embargo: 24/05/2020 Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.